HIV-1 Vaccine Shows Strong T-Cell Response in Phase 1 Study
|
The experimental HIV vaccine regimen exhibited an
acceptable safety profile and elicited robust immune responses in 99% of
trial participants from ... |
FDA slaps clinical hold on multiple Gilead HIV trials
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns. View article...